SD Biosensor and SJL Partners Complete Transaction to Acquire Meridian Bioscience PR Newswire CINCINNATI and SEOUL, South Korea, Jan. 31, 2023 CINCINNATI and SEOUL, South Korea, Jan. 31, 2023...
DoubleVerify Holdings to Join S&P SmallCap 600 PR Newswire NEW YORK, Jan. 25, 2023 NEW YORK, Jan. 25, 2023 /PRNewswire/ -- DoubleVerify Holdings Inc. (NYSE: DV) will replace Meridian...
Meridian Bioscience Announces Anticipated Closing Date of the Pending Merger PR Newswire CINCINNATI, Dec. 12, 2022 CINCINNATI, Dec. 12, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ:...
MERIDIAN BIOSCIENCE REPORTS FOURTH QUARTER AND FULL YEAR FISCAL 2022 OPERATING RESULTS PR Newswire CINCINNATI, Nov. 22, 2022 CINCINNATI, Nov. 22, 2022 /PRNewswire/ -- Meridian Bioscience, Inc...
MERIDIAN BIOSCIENCE REPORTS THIRD QUARTER FISCAL 2022 OPERATING RESULTS PR Newswire CINCINNATI, Aug. 5, 2022 CINCINNATI, Aug. 5, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. (NASDAQ: VIVO...
Meridian Bioscience Receives Re-Authorization from FDA for its Revogene® SARS-CoV-2 Molecular Assay PR Newswire CINCINNATI, July 29, 2022 CINCINNATI, July 29, 2022 /PRNewswire/ -- Meridian...
Meridian Bioscience, Inc. Enters into Agreement to Be Acquired by SD Biosensor and SJL Partners in $1.53 Billion All-Cash Transaction PR Newswire CINCINNATI and SEOUL, South Korea, July 7, 2022...
Meridian Bioscience Announces Preliminary Results for Fiscal 2022 Third Quarter PR Newswire CINCINNATI, July 7, 2022 CINCINNATI, July 7, 2022 /PRNewswire/ -- Meridian Bioscience, Inc. ("Meridian...
Meridian Launches New qPCR Master Mixes for Stool Samples to Accelerate Development of Molecular Assays PR Newswire CINCINNATI, June 20, 2022 CINCINNATI, June 20, 2022 /PRNewswire/ -- Meridian...
Meridian Bioscience responds to the Monkeypox Outbreak with its Inhibitor-Tolerant qPCR Master Mixes for the Development of Molecular Tests PR Newswire CINCINNATI, May 26, 2022 CINCINNATI, May...
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
Aucune Discussion Trouvée |
Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales